Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis - sprookjes - yvandenbroek - TriplyDB

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

http://www.wikidata.org/entity/Q29614337

about

Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans Essential thrombocythemia JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin Janus kinases in immune cell signaling The molecular mechanisms that control thrombopoiesis Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis Venous thromboembolic disease Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray Selectivity and therapeutic inhibition of kinases: to be or not to be?Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders Therapeutic targeting of Janus kinases Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo Recent advances in understanding myelofibrosis and essential thrombocythemia Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain Integration of Signaling Pathways with the Epigenetic Machinery in the Maintenance of Stem Cells Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis Genomic landscape of megakaryopoiesis and platelet function defects Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development Chronic neutrophilic leukemia: a clinical perspective JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F Clinical potential of pacritinib in the treatment of myelofibrosis Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy Genetics of myeloproliferative neoplasms

P2860

Q21133609-3E0E8932-82B3-4F4B-80C5-E1DD488C0E00 Q21202968-AF6C03EF-3445-47A3-81DC-C71D07B3E018 Q21285040-5C67E2EC-3250-425F-BCA6-823F2DE5E6F7 Q24297854-A9D66A36-32F4-4343-AE5C-7B97A60F145F Q24308570-82086863-F1E9-418E-B35F-6978166619D0 Q24318979-BA02081B-2FFE-412E-9783-B2E4C1B8D294 Q24322021-5CE4A7AD-467A-4BF8-BEA8-7D56C52DC183 Q24536138-715F3F7E-6880-4CEE-8DFA-EB0946879004 Q24568313-D12DADA2-CDAF-4B79-9974-5C3701124238 Q24609999-D243AE5F-289F-4F7C-9767-E569FEC03A47 Q24631121-4CB8A743-0D79-40DA-8C23-14AA5E663FBA Q24648438-CAF15F0A-F3C8-40B2-AA60-7FE23AB9BC12 Q24650855-8A98B54E-7CEC-4F05-8E7D-438D32A4947B Q24656006-ABF7258A-C7C6-48BA-9F9A-2B5609F253E6 Q24657681-14B433AE-6959-4024-BA23-439E434D7ED2 Q24658483-FDCA2A81-AA96-40E2-AFF1-9831F2F79B89 Q24671505-26C5EE26-BC27-4F9A-AFED-D44824B1AF01 Q24675681-95A8BEAD-DFCD-41B7-8CD5-731B0A28A94A Q24676526-52492F9E-91A7-4E7F-ABB4-7A04A306EBA8 Q24676798-F3AB1289-9657-4714-B67D-BAEB2AE2A693 Q24685447-041B8372-6013-463B-81FA-156969E9C489 Q24685474-8D23282F-FD21-402A-A9C6-5C7FCD2D54B5 Q24685620-F3820F72-79AA-414B-B5D0-09355EFBBC71 Q26748543-49AF2CA6-C1CD-4D5B-A67F-88322FE9D187 Q26750696-8EB01BDD-A498-465B-8DBD-447BCFF24121 Q26752940-CF3AD4B8-0A2C-4DF0-9D08-8B96AD4A68DA Q26765647-B41CCEE4-850C-40F6-A9D0-C830535E26CA Q26769986-BED2D3DE-C4D8-4C60-93D2-63BA52145F91 Q26770330-1E0E4E98-1FAC-4CDB-B83A-F6FC9F559C89 Q26770869-EA23342D-2750-4AAF-B4E2-4888A12C1F7A Q26774212-94B71BF9-2E11-4CC0-AAF7-A00A401E1DBA Q26778548-1421F1D6-B7F0-471B-A676-58DDDE6E0815 Q26778929-E007563C-BA22-4B1A-9939-929B6A8A297B Q26779947-70DBB46D-8F3A-41F8-B8E5-B1481ACCFEA2 Q26781167-1750F656-3744-40EC-B58D-703AE8C13333 Q26782539-C510D2EC-9C8C-4532-B20C-72B3F1693879 Q26795666-F88ABF95-5CD7-46E9-8B3B-0746CD0F8E89 Q26796450-04EA1282-699A-4A3C-B39C-15D44B16F7DF Q26798420-86189388-6393-4FDA-AAE2-CD16257ED40F Q26823651-2BBDA5EB-2DED-4470-8B2F-3C589B527397

P2860

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

http://www.wikidata.org/entity/Q29614337

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Activating mutation in the tyr ...... metaplasia with myelofibrosis

@ast

Activating mutation in the tyr ...... metaplasia with myelofibrosis

@en

type

label

Activating mutation in the tyr ...... metaplasia with myelofibrosis

@ast

Activating mutation in the tyr ...... metaplasia with myelofibrosis

@en

prefLabel

Activating mutation in the tyr ...... metaplasia with myelofibrosis

@ast

Activating mutation in the tyr ...... metaplasia with myelofibrosis

@en

P1433

Q29614337-2DBC6A89-BC01-4108-B197-FBEF08596349

P1476

Q29614337-4B0B6890-EF01-4EED-B273-FCD18E386701

P2093

Q29614337-058220CA-53D7-4BDB-8964-9F29EF825CA9

Q29614337-083C960B-E88C-4D70-88B5-ACBC18987EC2

Q29614337-11AA55E3-D2B6-4F1A-8E69-4391667518E7

Q29614337-1CB418E7-82AE-40E1-9A2E-04651019A065

Q29614337-23169B6A-A27F-44CA-8D72-2540AF3E8BD7

Q29614337-38D9810F-D2BF-41D3-914F-32CBE5E61919

Q29614337-46C182BD-1B2C-4A9B-9E03-96554D40F2FF

Q29614337-4F8B454A-20B6-47ED-B804-01216543D5A3

Q29614337-516A5167-0A9D-4158-A9EC-EA22DA2E424B

Q29614337-5F28E2B5-C080-4CE3-B342-F8AF774AA7AC

P304

Q29614337-C5D9724B-DA84-40F8-9D37-7CB9ECFF887D

P31

Q29614337-43AEB43E-607D-428F-B758-D400BE9643FF

P3181

Q29614337-7A2533B6-94F6-45D4-9DD5-7F96669B44B7

P356

Q29614337-2A8E0166-ED71-4DD8-A012-844945BCCCE5

P407

Q29614337-7E193C9B-710C-4313-8448-9D0A18582478

P433

Q29614337-7E778C52-563B-45BF-BBF1-69E4D6D66C2D

P478

Q29614337-F0D10963-6487-4D8B-8EC0-2DDFF7FCB868

P50

Q29614337-3D2BBD8B-525C-4618-B5CB-2444B749FE90

Q29614337-9D177019-9D5D-4AB0-A6DA-9CED9C3ED401

Q29614337-C32E2034-745B-4310-9253-429D38C16586

Q29614337-E13337D6-F827-4677-96EF-D4F0F6D5B457

P577

Q29614337-19FD7417-077D-4F57-B11C-CCC19ADC0067

P5875

Q29614337-F6D24857-1AFB-43F8-9D1B-D6C5B80D1414

P698

Q29614337-DAEB50B6-BA00-44E0-BA4B-8C54E7F3CEBE

P3181

P356

J.CCR.2005.03.023

P1433

P1476

Activating mutation in the tyr ...... metaplasia with myelofibrosis

@en

P2093

Alan D'Andrea

http://www.w3.org/2001/XMLSchema#string

Ayalew Tefferi

http://www.w3.org/2001/XMLSchema#string

Benjamin L Ebert

http://www.w3.org/2001/XMLSchema#string

D Gary Gilliland

http://www.w3.org/2001/XMLSchema#string

Gerlinde Wernig

http://www.w3.org/2001/XMLSchema#string

Iwona Wlodarska

http://www.w3.org/2001/XMLSchema#string

James D Griffin

http://www.w3.org/2001/XMLSchema#string

Jeffrey C Lee

http://www.w3.org/2001/XMLSchema#string

Jennifer Adelsperger

http://www.w3.org/2001/XMLSchema#string

Jennifer J Clark

http://www.w3.org/2001/XMLSchema#string

P304

387-397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1269787

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CCR.2005.03.023

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Peter Vandenberghe

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7898918

http://www.w3.org/2001/XMLSchema#string

P698

15837627

http://www.w3.org/2001/XMLSchema#string